Replies to post #143880 on Biotech Values

[DewDiligence]

Bet it would be easier to co-formulate Fovista with AGN's DARPin :)

No doubt it would be. In all seriousness, AGN could be a potential suitor for Ophthotech; back-of-the-eye diseases are a major hole in AGN’s portfolio, but it’s not from a lack of trying.

[DewDiligence]

Fovista phase-2b data will be presented at AAO on 11/10/12:

http://finance.yahoo.com/news/positive-results-phase-2b-study-100000708.html